{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["10(10)"],"submitter":["Davis EJ"],"pubmed_abstract":["Background
OX40 is a costimulatory receptor upregulated on antigen-activated T cells and constitutively expressed on regulatory T cells (Tregs). INCAGN01949, a fully human immunoglobulin G1κ anti-OX40 agonist monoclonal antibody, was designed to promote tumor-specific immunity by effector T-cell activation and Fcγ receptor-mediated Treg depletion. This first-in-human study was conducted to determine the safety, tolerability, and preliminary efficacy of INCAGN01949.Methods
Phase I/II, open-label, non-randomized, dose-escalation and dose-expansion study conducted in patients with advanced or metastatic solid tumors. Patients received INCAGN01949 monotherapy (7-1400 mg) in 14-day cycles while deriving benefit. Safety measures, clinical activity, pharmacokinetics, and pharmacod"],"journal":["Journal for immunotherapy of cancer"],"pagination":["e004235"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9628691"],"repository":["biostudies-literature"],"pubmed_title":["First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors."],"pmcid":["PMC9628691"],"pubmed_authors":["Condamine T","Clark J","Janik JE","Hari Dass P","Davis EJ","Berthold D","Blagden SP","Cardin DB","Orcurto A","Mehnert JM","Miller RE","Kristeleit R","Cho DC","Vieito M","Spencer K","Martin-Liberal J","Pulini J","Chen X"],"additional_accession":[]},"is_claimable":false,"name":"First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors.","description":"Background
OX40 is a costimulatory receptor upregulated on antigen-activated T cells and constitutively expressed on regulatory T cells (Tregs). INCAGN01949, a fully human immunoglobulin G1κ anti-OX40 agonist monoclonal antibody, was designed to promote tumor-specific immunity by effector T-cell activation and Fcγ receptor-mediated Treg depletion. This first-in-human study was conducted to determine the safety, tolerability, and preliminary efficacy of INCAGN01949.Methods
Phase I/II, open-label, non-randomized, dose-escalation and dose-expansion study conducted in patients with advanced or metastatic solid tumors. Patients received INCAGN01949 monotherapy (7-1400 mg) in 14-day cycles while deriving benefit. Safety measures, clinical activity, pharmacokinetics, and pharmacod","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Oct","modification":"2026-06-08T06:50:03.821Z","creation":"2026-06-08T03:14:30.525Z"},"accession":"S-EPMC9628691","cross_references":{"pubmed":["36316061"],"doi":["10.1136/jitc-2021-004235"]}}